Cargando…
Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus
ClpC1 is an emerging new target for the treatment of Mycobacterium tuberculosis infections, and several cyclic peptides (ecumicin, cyclomarin A, and lassomycin) are known to act on this target. This study identified another group of peptides, the rufomycins (RUFs), as bactericidal to M. tuberculosis...
Autores principales: | Choules, Mary P., Wolf, Nina M., Lee, Hyun, Anderson, Jeffrey R., Grzelak, Edyta M., Wang, Yuehong, Ma, Rui, Gao, Wei, McAlpine, James B., Jin, Ying-Yu, Cheng, Jinhua, Lee, Hanki, Suh, Joo-Won, Duc, Nguyen Minh, Paik, Seungwha, Choe, Jin Ho, Jo, Eun-Kyeong, Chang, Chulhun L., Lee, Jong Seok, Jaki, Birgit U., Pauli, Guido F., Franzblau, Scott G., Cho, Sanghyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395927/ https://www.ncbi.nlm.nih.gov/pubmed/30602512 http://dx.doi.org/10.1128/AAC.02204-18 |
Ejemplares similares
-
Rufomycin Exhibits Dual Effects Against Mycobacterium abscessus Infection by Inducing Host Defense and Antimicrobial Activities
por: Park, Cho Rong, et al.
Publicado: (2021) -
Residual Complexity
Does Impact Organic Chemistry
and Drug Discovery: The Case of Rufomyazine and Rufomycin
por: Choules, Mary P., et al.
Publicado: (2018) -
Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening
por: Grzelak, Edyta M., et al.
Publicado: (2019) -
Structure of the N-terminal domain of ClpC1 in complex with the antituberculosis natural product ecumicin reveals unique binding interactions
por: Wolf, Nina M., et al.
Publicado: (2020) -
ClpC2 protects mycobacteria against a natural antibiotic targeting ClpC1-dependent protein degradation
por: Taylor, Gabrielle, et al.
Publicado: (2023)